RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
0 hedge funds and large institutions have $0 invested in RAPT Therapeutics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 104 closing their positions.
100% less funds holding
Funds holding: 105 → 0 (-105)
100% less funds holding in top 10
Funds holding in top 10: 9 → 0 (-9)
100% less capital invested
Capital invested by funds: $1.02B → $0 (-$1.02B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 104
109.39% less ownership
Funds ownership: 109.39% → 0% (-109%)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MVM
Medicxi Ventures Management
St. Helier,
Jersey
|
-$94.6M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$87.5M |
| 3 |
FIS
FCPM III Services
Naarden,
Netherlands
|
-$62.1M |
| 4 |
O
OrbiMed
New York
|
-$55.6M |
| 5 |
RI
RTW Investments
New York
|
-$55.5M |
RAPT Hedge Fund Activity: Q1 2026 in Review
0 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q1 2026, worth a combined $0 — down 100% from $1.02B a quarter earlier.
Sellers outnumbered buyers: 104 funds closed out of RAPT and 0 opened new positions — a net loss of 104 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Medicxi Ventures Management, exiting entirely with an estimated $94.6M sold.
- 0 institutional investors held RAPT Therapeutics (RAPT) as of Q1 2026, down from 105 in Q4 2025.
- Funds reported $0 of RAPT Therapeutics stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new RAPT Therapeutics positions in Q1 2026 and 104 closed out, a net change of -104 holders.
- The largest RAPT Therapeutics seller in Q1 2026 was Medicxi Ventures Management, an estimated $94.6M sold.
Based on aggregated 13F filings for Q1 2026.